MEDIA ADVISORY, Aug. 21, 2006 (PRIMEZONE) --
What: Dr. Charles Bugg, Chairman and Chief Executive Officer of BioCryst Pharmaceuticals, Inc. (BCRX), will preside over the opening bell to celebrate its 20-year business anniversary. Where: NASDAQ MarketSite - 4 Times Square - 43rd & Broadway - Broadcast Studio When: Tuesday, August 22nd, 2006 at 9:30 a.m. EDT Contacts: John Nugent Investor Relations 205-444-4600 firstname.lastname@example.org NASDAQ MarketSite: Stephanie Lowenthal; 646.441.5220
The opening bell is available from 9:20 a.m. to 9:35 a.m. on uplink IA-5 C-band/transponder 14. The downlink frequency is 3980 horizontal; audio: 6.2/6.8. The feed can also be found on Waterfront fiber 1623. If you have any questions, please contact Stephanie Lowenthal at (646) 441-5220.
To obtain a hi-resolution photograph of the Market Open, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market open of your choice.
About BioCryst Pharmaceuticals, Inc. (BCRX):
BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential commercialization including Fodosine(tm) in oncology, BCX-4208 in transplantation and autoimmune diseases, peramivir in seasonal and life-threatening influenza, and BCX-4678 in hepatitis C. BioCryst has a worldwide partnership with Roche for the development and commercialization BCX-4208 and is collaborating with Mundipharma Holdings for the development and commercialization of Fodosine(tm) in markets across Europe, Asia, Australia and certain neighboring countries. For more information about BioCryst, please visit the company's web site at http://www.biocryst.com.